Clinical Trial

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Study acronym: BRALLA
Recruiting
View on ClinicalTrials.gov →
Summary
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-07-17; most recent amendment 2025-05-03.
Trial Details
NCT Number NCT05959720
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Collaborators: Servier
Conditions Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality, Chemotherapeutic Toxicity
Enrollment 180 participants
Start Date 2023-09-05
Primary Completion 2028-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-05-07